Why Easy Stem Cells Raise Hard Ethical Questions
By Brendan Foht,
The Public Discourse
| 02. 11. 2014
Late last month, Haruko Obokata and her colleagues at the RIKEN Center for Developmental Biology in Kobe, Japan
reported that they had discovered a surprising new technique for making stem cells. In a
pair of
articles published in the journal
Nature, they claimed that ordinary mouse cells could be made pluripotent (that is, having the ability to develop into any of the body’s tissue types) by exposing them to various forms of stress, such as acidic conditions.
The most obvious practical application of this new technique is that it could serve as a new source of pluripotent stem cells for regenerative medicine or for research. Initial results suggest that the technique is not only simpler than the genetic engineering techniques developed in 2006 to create induced pluripotent stem (iPS) cells, but also much more efficient at transforming cells to a pluripotent state.
There is still more work to be done before we know whether this procedure will work on the cells of adult humans. There are many differences between the stem cells of mice and humans, and the researchers...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...